NCT05780749 - A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

November 23, 2023

Primary Completion Date

February 2, 2025

Study Completion Date

February 2, 2025

Conditions

Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

DDI-IBS-001

The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.

OTHER

DDDI-IBS-001 placebo

The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.

Trial Locations (11)

1070

CUB Hôpital Erasme, Brussels

1090

UZ Brussel, Jette

1200

Cliniques Universitaires Saint-Luc, Brussels

3000

UZ Leuven, Leuven

4000

CHU Liege, Liège

Clinique CHC Mont-Legia, Liège

4100

Centre Hospitalier du Bois de l'Abbaye, Seraing

7800

Centre Hospitalier EpiCURA, Ath

8000

AZ Sint-Jan, Bruges

8310

AZ Sint-Lucas, Bruges

9000

AZ Sint-Lucas, Ghent

All Listed Sponsors

lead

Biokuris s.a.

INDUSTRY